ClinicalTrials.gg

Program

BGM1812

A development code. Also written as “BGM1812 injection / plcaebo”.

Its studies are mostly in Obesity · Overweight, led by BrightGene Bio-Medical Technology.

Furthest: phase 2, since Oct 30, 20263 company-led studies, 1 open or runningNext primary completion: Aug 1, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
BrightGene Bio-Medical Technology31 open or runningphase 2since Oct 30, 2026Oct 29, 2025Aug 1, 2027phase 2 · NCT07918625

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 29, 2025First study: phase 1 study in OverweightFirst studyNCT07224399 · 60 enrolled · United States
  2. Dec 7, 2025Phase 1 study in OverweightNCT07294235 · 60 enrolled · China
  3. Oct 30, 2026Phase 2 study in OverweightPhase 2 reachedNCT07918625 · 160 planned · China

Ahead

  1. Aug 1, 2027Primary completion: phase 2 study in OverweightNCT07918625

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07918625Overweight · China2Not yet recruitingAug 1, 2027160
NCT07294235Overweight · China1CompletedJun 5, 202660
NCT07224399Overweight · United States1CompletedJul 17, 202660

How it is read

Names in the registry

  • “BGM1812”, 4 entries
  • “BGM1812 injection / plcaebo”, 4 entries

Codes read as this program: BGM1812.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.